Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Bluebird Bio
Bluebird Bio
Bluebird Bio submits BLA for sickle cell disease gene therapy
Biopharma Reporter
Mon, 04/24/23 - 11:39 am
Bluebird Bio
sickle cell disease
lovo-cel
FDA
Bluebird to miss Q1 deadline for lovo-cel filing, shares sliced
Endpoints
Wed, 03/29/23 - 04:04 pm
Bluebird Bio
sickle cell disease
gene therapy
FDA
lovo-cel
Medicaid, with planned payment pilot, girds for influx of pricey gene therapies
BioPharma Dive
Tue, 02/21/23 - 04:37 pm
Medicaid
sickle cell disease
gene therapies
Bluebird Bio
Vertex Pharmaceuticals
CRISPR Therapeutics
Bluebird hopes to raise upwards of $100M by selling shares
Endpoints
Wed, 01/18/23 - 12:08 pm
Bluebird Bio
Moderna Gets Good News, but Another Biotech Stock Is Falling Again
Motley Fool
Wed, 01/18/23 - 09:50 am
Moderna Therapeutics
RSV
Bluebird Bio
NASDAQ
FDA Lifts Partial Clinical Hold On Bluebird Bio's Sickle Cell Disease Studies
NASDAQ
Mon, 12/19/22 - 10:59 am
Bluebird Bio
FDA
clinical trials
lovo-cel
sickle cell disease
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
BioPharma Dive
Mon, 12/12/22 - 10:56 pm
ASH 2022
JNJ
talquetamab
Multiple Myeloma
Argenx
Bluebird Bio
Vyvgart
ITP
ASH: Despite partial clinical hold, bluebird's sickle cell gene therapy remains on track
Fierce Pharma
Sun, 12/11/22 - 01:34 pm
Bluebird Bio
ASH 2022
Zynteglo
sickle cell disease
gene therapy
lovo-cel
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
Benzinga
Wed, 11/30/22 - 10:47 am
Bluebird Bio
priority review vouchers
FDA
Argenx
ASH preview – waiting for Editas
EP Vantage
Wed, 11/9/22 - 10:40 am
ASH 2022
sickle cell disease
Bluebird Bio
Sangamo BioSciences
Novartis
Editas Medicine
gene therapy
Vertex Pharmaceuticals
Sanofi
Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies
Fierce Pharma
Thu, 11/3/22 - 11:02 am
ICER
drug pricing
gene therapy
Biomarin
CSL
Bluebird Bio
hemophilia
Bluebird wins FDA approval of gene therapy for rare brain disorder
BioPharma Dive
Sun, 09/18/22 - 10:23 pm
Bluebird Bio
gene therapy
cALD
Skysona
FDA
Go or no go? Bristol’s Tyk2 test
EP Vantage
Wed, 08/31/22 - 10:15 am
FDA
Bristol Myers Squibb
deucravacitinib
Amylyx Pharmaceuticals
ALS
AMX0035
Ferring Pharmaceuticals
microbiome
RBX2660
Revance Therapeutics
Bluebird Bio
Spectrum Pharmaceuticals
JNJ
Oncopeptides
bluebird bio Scores First U.S. Approval for Lentiviral Vector Gene Therapy
BioSpace
Wed, 08/17/22 - 11:34 pm
Bluebird Bio
FDA
gene therapy
beta thalassemia
Zynteglo
beti-cel
Go or no go? J&J’s bispecific FDA first
EP Vantage
Thu, 07/28/22 - 11:04 am
JNJ
Amicus Therapeutics
Acadia Pharma
Bluebird Bio
FDA
FDA Has Ways to Go to Keep Pace with 2020/21 Approvals
BioSpace
Wed, 07/6/22 - 11:05 am
FDA
drug approvals
Amicus
Bluebird Bio
Bristol Myers Squibb
Eli Lilly
Marinus Pharma
Amylyx
Novartis
bluebird bio Soars as FDA Adcom Recommends Second Gene Therapy
BioSpace
Sun, 06/12/22 - 08:30 pm
Bluebird Bio
FDA
lentiviral vectors
beti-cel
FDA panel backs Bluebird gene therapy despite safety risks
BioPharma Dive
Fri, 06/10/22 - 10:56 am
Bluebird Bio
FDA
eli-cel
cALD
Bluebird bio’s future in balance as FDA weighs gene therapy approvals
BioPharma Dive
Thu, 06/9/22 - 10:32 am
Bluebird Bio
gene therapy
bluebird bio Blazes Trail for Lentiviral Vectors at Upcoming FDA Meeting
BioSpace
Tue, 06/7/22 - 11:57 pm
Bluebird Bio
lentiviral vectors
FDA
cell therapy
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »